GLP-1_与百泌达作用机制.pptVIP

CITATIONBarnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-2348. SEEpg 2341 Figure 4 (for slide data) pg 2338 “Change in body weight” and pg 2340 1st column (for DISCUSSION); and pg 2335 “Study design” (for background information) DISCUSSION During exenatide treatment, a mean decrease in body weight of -2.0 ± 0.4 kg occurred in the first period and ?2.2 ± 0.4 kg during the second period. In contrast, during insulin glargine treatment, mean weight increases of approximately +1.0 ± 0.4 kg (first period) and +2.3 ± 0.4 kg (second period) were observed. Change in body weight from study baseline to endpoint was significantly different between treatments (exenatide, ?1.6 ± 0.3 kg; insulin glargine, 0.6 ± 0.3; p.001) STUDYH8O-MC-GWAO BACKGROUND Randomised, open-label, 2-period crossover noninferiority study of patients with type 2 diabetes previously uncontrolled with MET or an SFU. Exenatide and insulin glargine treatments were administered for 16 weeks each and prestudy dose of MET or SFU was continued. Exenatide was administered twice daily as subcutaneous injection, 60 min before AM and PM meals at 5 μg for first 4 weeks, 10 μg exenatide after 4 weeks. Once-daily insulin glargine treatment was initiated at 10 IU, and was increased weekly by 8, 6, 4, or 2 IU daily if the mean fasting serum glucose (FSG) level on two consecutive days was 10 mmol/L, 7.8 to 10 mmol/L, 6.7 to 7.8 mmol/L, or 5.6 to 6.7 mmol/L, respectively. However, if the mean FSG level was less than 4 mmol/L at any time during the previous week, the insulin glargine dose was not adjusted. CITATIONBarnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabete